Key result
The heart-rate corrected J-Tpeak interval (J-Tpeakc) improved detection of late sodium current block compared to using QTc alone (AUC 0.83 vs 0.72, p<0.001).
Why the study?
Does the J-Tpeakc interval improve the detection of drug-induced late sodium current block compared to QTc alone?
RCT (n=21)
Randomized, cross-over
No
Does the J-Tpeakc interval improve the detection of drug-induced late sodium current block compared to QTc alone?
Absolute Event Rate: 0.83% vs 0.72%
p-value: p=<0.001
The J-Tpeakc interval is a superior ECG biomarker compared to QTc alone for detecting drug-induced late sodium current block, which may aid in preclinical proarrhythmic risk assessment.
No takes yet. Share an insight, caveat, or question.
J-Tpeakc may refine ECG detection of late sodium current block; leaves open its adoption in proarrhythmic risk assessment.
Vicente et al. (2016) conducted an RCT in Healthy subjects (n=21). Late sodium current blockers (mexiletine or lidocaine) combined with dofetilide vs. Selective hERG potassium channel blocker (dofetilide) alone was evaluated on AUC for detecting late sodium current block (95% CI 0.80-0.87, p=<0.001). The heart-rate corrected J-Tpeak interval (J-Tpeakc) improved detection of late sodium current block compared to using QTc alone (AUC 0.83 vs 0.72, p<0.001).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: